Caffeine: Public Concern and the Precautionary Principle

Abstract

Get full access to this article

View all access options for this article.

References

James

. Coffee and mortality: urgent need for clinical trials to assess putative benefits and harms. J Caffeine Res, 2012; 2:53–54.

Letter from Senator R. J. Durbin to M. Hamburg, Commissioner, FDA April 3, 2012. http://durbin.senate.gov/public/index.cfm/files/serve?File_id=6657cb3d-33a8-4108-8292-7139d0b3b712. 2013 February 3.

Letter from J. Ireland, Assistant Commissioner, FDA to Senator R. J. Durbin August 10, 2012. http://durbin.senate.gov/public/index.cfm/files/serve?File_id=17eadaa1-85e7-4ceb-a827-be244fbddfa5. 2013 February 3.

Letter from Senators R. J. Durbin and R. Blumethal to M. Hamburg, Commissioner, FDA September 11, 2012. http://durbin.senate.gov/public/index.cfm/files/serve?File_id=fe44b78e-32ae-41a0-8a61-2ddf14ab95d1. 2013 February 3.

Letter from M. Mital, Acting Assistant Commissioner, FDA to Senator R. J. Durbin November 21, 2012. http://durbin.senate.gov/public/index.cfm/files/serve?File_id=60fccdd9-7e60-45d4-b529-4bf472cc6eee. 2013 February 3.

James

. A critical review of dietary caffeine and blood pressure: relationship that should be taken more seriously. Psychosom Med, 2004; 66:63–71.

Juliano

, Griffiths

. A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features. Psychopharmacology, 2004; 176:1–29.

James

, Sengpiel

, Brantsaeter

. Dietary caffeine and pregnancy outcomes: a roundtable discussion. J Caffeine Res, 2013; 3:3–8.

James

. Coffee and mortality: urgent need for clinical trials to assess putative benefits and harms. J Caffeine Res, 2012; 2:149–152.

10.

Rose

. Strategy of prevention: lessons from cardiovascular disease. Br Med J, 1981; 282:1847–1851.